57 reports

They also have applications in bone and inflammation treatment.

  • Protein Therapy
  • North America
  • United States
  • World
  • Agilent Technologies, Inc.

The drug candidate is a recombinant galectin-## protein.

  • Protein Therapy
  • Therapy
  • World
  • Product Initiative
  • Strykagen Corp.
  • Gene Therapy for Hemophilia A
  • ET-3I - DRUG PROFILE

No specific treatment was given for the anti-OBI-## antibodies.

  • Blood Disease
  • Medical Biotechnology
  • Protein Therapy
  • Therapy
  • United States

Of these proteins, albumin accounts for ##%, globulins for ##%, coagulation for ##% and other proteins for the remaining ##% share.

  • Blood Supply
  • Protein Therapy
  • World
  • Forecast
  • Grifols, S.A.

The patients had tested negative for pre-existing anti-AAV## NAbs using a green fluorescent protein-based (GFP) assay before receiving treatment.

  • Blood Disease
  • Protein Therapy
  • United States
  • Product Initiative
  • uniQure N.V.

PLASMA PROTEIN THERAPIES ARE USED TO TREAT RARE AND CHRONIC DISEASES.

  • Blood Disease
  • Blood Supply
  • Healthcare
  • Hospital
  • Protein Therapy
  • RESOLVED BY THE EGM HAS BECOME EFFECTIVE.

THE DRUG CANDIDATE IS A PROTEIN AND CELLULAR BASED THERAPY BASED RECOMBINANT ADENO-ASSOCIATED VIRUS (RAAV) BIOLOGICAL NANOPARTICLE.

  • Blood Disease
  • Protein Therapy
  • Therapy
  • United States
  • Product Initiative

The Company is developing OPRX-## to be the first ever oral protein treatment, as currently there are no other oral protein treatments available.

  • Protein Therapy
  • Brazil
  • United States
  • Company
  • Protalix BioTherapeutics, Inc.

HUMAN PROTEIN AND THE COMPANY WAS THE FIRST ONE TO MAKE VIRUS INACTIVE FACTOR VIII PRODUCT.

  • Protein Therapy
  • World
  • Baxter International Inc.
  • Biotest AG
  • CSL Limited

Grifols is one of the world top three producers of plasma-derived therapies.

  • Blood Disease
  • Clinical Trial
  • CT Scan
  • In Vitro Diagnostic Reagent
  • Protein Therapy
  • MARKET SEGMENTATION - ASIA-PACIFIC
  • MARKET DYNAMICS

Its Biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy, and hormone replacement therapy.

  • Protein Therapy
  • United States
  • Company
  • Market Segment
  • Bio-Rad Laboratories, Inc.

SMAD## PROTEIN ACTS AS TGF BETA RECEPTOR TYPE ## ANTAGONIST.

  • Medical Supply
  • Protein Therapy
  • Wound Care
  • United States
  • Product Initiative

It is engineered by fusing factor IX to the Fc portion of immunoglobulin G subclass ##, or IgG## (a protein commonly found in the body), enabling Alprolix to use a naturally occurring pathway to extend the time the therapy remains in the body (half-life).

  • Blood Disease
  • Medical Biotechnology
  • Protein Therapy
  • Therapy
  • United States

Additionally, we are screening patients in Australia for our Phase ## clinical trial of FPT##, our first-in-class CD## fusion protein.

  • Protein Therapy
  • United States
  • Company
  • Company Financials
  • Five Prime Therapeutics, Inc.

ACQUIRED THERAPY BUSINESS OF BIOTEST PHARMACEUTICALS CORPORATION, A ##% MINUS ONE SHARE OF ADMA.

  • Protein Therapy
  • Market Size
  • AbbVie Inc.
  • Pfizer Inc.
  • Sanofi S.A.

The prominent features of this report are - ##.

  • Clinical Trial
  • Digestive System Disorder
  • Pharmaceutical
  • Protein Therapy
  • World

MANF Therapeutics is the front-runner and primary worldwide intellectual property (IP) holder for MANF-based therapies including protein therapy, gene therapy and cell therapy.

  • Clinical Trial
  • Neurological Disorder
  • Protein Therapy
  • World
  • Neuren Pharmaceuticals Limited
  • 3. GDCT ID IS THE UNIQUE ID OF GLOBALDATA'S PHARMA INTELLIGENCE CENTER CLINICAL TRIAL DATABASE

The study is being conducted at the Cincinnati Children' s Hospital Medical Center, one of the NIAID-funded Vaccine and Treatment Evaluation Units (VTEUs).

  • Clinical Trial
  • Pharmaceutical
  • Protein Therapy
  • World
  • Product Initiative
  • ET-3 - DRUG PROFILE

No specific treatment was given for the anti-OBI-## antibodies.

  • Blood Disease
  • Medical Biotechnology
  • Protein Therapy
  • United States
  • Alnylam Pharmaceuticals, Inc.

ACQUIRED THERAPY BUSINESS OF BIOTEST PHARMACEUTICALS CORPORATION, A ##% MINUS ONE SHARE OF ADMA.

  • Protein Therapy
  • Market Size
  • AbbVie Inc.
  • Pfizer Inc.
  • Sanofi S.A.

One case of nonserious rash and one case of myalgia were reported to be treatment-related.

  • Blood Disease
  • Protein Therapy
  • Therapy
  • Novo Nordisk Group
  • Pfizer Inc.

## ## ##. ## ## ##. ## GlaxoSmithKline Plc Samsung Bioepis Co Ltd South Korea ##. ## ##. ## ##. ## ## ## ##. ## ## ##. ## UCB SA ##. ## ##. ## ##. ## ##. ## ## ## ##. ## ## ##. ## ## ##. ## - ##. ## ## ## ##. ## ## - Biogen Inc United States ##. ## ##. ## ##. ## ##. ## ## ## ##. ## ## ##. ## Gilead Sciences Inc Corbus

  • Arthritis
  • Medical Biotechnology
  • Monoclonal Antibody
  • Pharmaceutical
  • Protein Therapy

THEY ACT BY TARGETING PROTEIN PATCHED HOMOLOG ##.

  • Hospital
  • Medical Biotechnology
  • Pharmaceutical
  • Protein Therapy
  • Therapy

Most of the adverse effects (AEs) were grade ## or ##.

  • Cancer
  • Medical Biotechnology
  • Monoclonal Antibody
  • Protein Therapy
  • Therapy

The prominent features of this report are - ##.

  • Clinical Trial
  • Infectious Disease
  • Pharmaceutical
  • Protein Therapy
  • Tuberculosis

PROTEIN EXPRESSION OF CTGF, FIBRONECTIN, PDGF-BB, TIMP-## AND MCP-## DETECTED IN THE CULTURE MEDIA.

  • Genitourinary System Disease
  • Hospital
  • Pharmaceutical
  • Protein Therapy
  • Therapy
  • Orphan Dermatological Diseases, Global, Number and Aggregate Deal Value of Co-development Deals by Molecule Type

Arthritis Research and Therapy. ##(##).

  • Dermatological Condition
  • Pathology
  • Protein Therapy
  • Therapy
  • Deals & Alliance

Protein expression of CTGF, fibronectin, PDGF-BB, TIMP-## and MCP-## detected in the culture media.

  • Genitourinary System Disease
  • Pathology
  • Pharmaceutical
  • Protein Therapy
  • Therapy
  • BAYER HEALTHCARE: YOY REVENUE AND GROWTH RATE OF KOGENATE 2013-2015 ($ BILLIONS)
  • In March 2016, the company received US FDA approval for its recombinant hemophilia A drug, Kovaltry

Other mutations reduce the amount of protein but do not eliminate the protein' s activity, leading to mild or moderate hemophilia.

  • Protein Therapy
  • Baxalta Incorporated
  • Bayer AG
  • Biogen Idec Inc.
  • Grifols, S.A.

COMPARED TO THE CONTROL GROUP, CD##MAB TREATMENT SIGNIFICANTLY DECREASED GENES EXPRESSION RELATED TO OXIDATIVE STRESS (SOD-##, GPX-##, AND TXN), THE INFLAMMATORY RESPONSE (IL-##, IL-##, INF-G AND TGF-B), AS WELL AS REDUCED PROTEIN LEVELS OF BAX, CASPASE-##, MMP##, AND M

  • Cardiovascular Disease
  • Hospital
  • Pharmaceutical
  • Protein Therapy
  • Therapy